Butador
Active substance
ATC code
Species
Horses, dogs, cats
Indications
Horses
As an analgesic
For the short term relief of pain such as colic of gastrointestinal tract origin.
As a sedative and pre-anaesthetic
In combination with α2-adrenoceptor agonists (detomidine, romifidine, xylazine): For therapeutic and diagnostic procedures such as minor standing surgery and sedation of intractable patients.
Dogs, cats
As an analgesic
For relief of moderate visceral pain e.g. pre- and post-surgical as well as post-traumatic pain.
As a sedative
In combination with α2-adrenoceptor agonists (medetomidine).
As a pre-anaesthetic
Part of anaesthetic regime (medetomidine, ketamine).
Dose to be administered and administration route
For intravenous (i.v.), intramuscular (i.m.) or subcutaneous (s.c.) use.
Horses:Intravenous
Dogs: Intravenous, subcutaneous or intramuscular
Cats:Intravenous or subcutaneous
To ensure a correct dosage, body weight should be determined as accurately as possible.
Horses
As an analgesic
Monotherapy:
0.1 mg/kg (1 ml/100 kg bw) i.v.
As a sedative and as a pre-anaesthetic
With detomidine:
Detomidine: 0.012 mg/kg i.v., followed within 5 minutes by
Butorphanol: 0.025 mg/kg (0.25 ml /100 kg bw) i.v.
With romifidine:
Romifidine: 0.05 mg/kg i.v., followed within 5 minutes by
Butorphanol: 0.02 mg/kg (0.2 ml /100 kg bw) i.v..
With xylazine:
Xylazine: 0.5 mg/kg i.v., followed after 3 - 5 minutes by
Butorphanol: 0.05 – 0.1 mg/kg (0.5 - 1 ml /100 kg bw) i.v..
Dogs
As an analgesic
Monotherapy:
0.1 - 0.4 mg/kg (0.01 – 0.04 ml/kg bw) slowly i.v. (in the lower to medium dose range) as well as i.m., s.c..
For post-operative pain control the injection should be administered 15 minutes before the end of anaesthesia in order to achieve sufficient pain relief during the recovery phase.
As a sedative
With medetomidine:
Butorphanol: 0.1 mg/kg (0.01 ml/kg bw) i.v., i.m.
Medetomidine: 0.01 mg/kg i.v., i.m.
As a pre-anaesthetic
With medetomidine and ketamine:
Butorphanol: 0.1 mg/kg (0.01 ml/kg bw) i.m.
Medetomidine: 0.025 mg/kg i.m., followed after 15 minutes by
Ketamine: 5 mg/kg i.m.
It is only possible to use atipamezole 0.1 mg/kg body weight for medetomidineantagonisation when ketamine action has ceased.
Cats
As an analgesic
Monotherapy:
15 minutes prior to recovery either: 0.4 mg/kg (0.04 ml/kg bw) s.c. or: 0.1 mg/kg (0.01 ml/kg bw) i.v.
As a sedative
With medetomidine:
Butorphanol: 0.4 mg/kg (0.04 ml/ kg bw) s.c.
Medetomidine: 0.05 mg/kg s.c.
For wound debridement an additional local anaesthesia is recommended.
Medetomidine-antagonisation is possible with atipamezole 0.125 mg/kg body weight.
As a pre-anaesthetic
With medetomidine and ketamine:
Butorphanol: 0.1 mg/kg (0.01 ml/ kg bw) i.v.
Medetomidine: 0.04 mg/kg i.v. Ketamine: 1.5 mg/kg i.v.
It is only possible to use atipamezole 0.1 mg/kg body weight for medetomidine– antagonisation when ketamine action has ceased.
Butorphanol is intended for use where short (horses and dogs) and short to medium (cats) analgesia is required. The dose may be repeated as required. The need for and timing of repeated treatment will be based on clinical response. For information on the duration of analgesia see section 4.2.
Rapid intravenous injection should be avoided.
The stopper must not be punctured more than 25 times.
Adverse reactions
Horses:
Very common (>1 animal / 10 animals treated): |
|
Undetermined frequency (cannot be estimated from the available data): |
Involuntary movement[3]; Digestive tract hypomotility[4]; Respiratory depression[5]; Cardiac depression. |
1 Lasting about 3 to 15 minutes.
2 Mild.
3 Running movements.
4 Mild and transient. Any reduction of gastrointestinal motility caused by butorphanol may be enhanced by the concomitant use of α2-agonists.
5 The respiratory depressive effects of α2-agonists may be enhanced by concomitant butorphanol, particularly if respiratory function is already impaired.
Dogs:
Rare (1 to 10 animals / 10,000 animals treated): |
Ataxia; Anorexia; Diarrhoea. |
Undetermined frequency (cannot be estimated from the available data): |
Respiratory depression; Cardiac depression; Injection site pain1; Digestive tract hypomotility. |
1 Associated with intramuscular administration.
Cats:
Rare (1 to 10 animals / 10,000 animals treated): |
Ataxia; Anorexia; Diarrhoea. |
Undetermined frequency (cannot be estimated from the available data): |
Respiratory depression; Cardiac depression; Injection site pain1; Digestive tract hypomotility; Excitation, Anxiety; Sedation, Mydriasis, Disorientation; Dysphoria. |
1 Associated with intramuscular administration.
Reporting adverse events is important. It allows continuous safety monitoring of a veterinary medicinal product. Reports should be sent, preferably via a veterinarian, to either the marketing authorisation holder or its local representative or the national competent authority via the national reporting system. See the package leaflet for respective contact details.
Dispensing
POM-V - Prescription Only Medicine – Veterinarian
PRICE | Only for registered vets. Create a free profile to access all features.. Login |
---|---|
Art. Nr. | 57446/5006 |